Table 3 Demographic data of ABPA patients with and without AR receiving omalizumab
All participants (n = 14) | With AR (n = 10) | Without AR (n = 4) | P | |
|---|---|---|---|---|
Age, years | 53 (range, 18–82) | 54 (range, 18–82) | 53 (range, 47–61) | 0.88 |
Female | 6 | 6 | 0 | 0.09 |
History of asthma, years | 9 (range, 0.5–30) | 10 (range, 0.5–30) | 4.5 (range, 1.8–10.8) | 0.25 |
Antifungal agents | 4 | 3 | 1 | 0.001 |
Bronchiectasis | 7 | 5 | 2 | 1.00 |
Follow-up (month) | 21 (range, 6–40) | 23 (range, 8–40) | 21 (range, 15–26) | 0.78 |
Duration of omalizumab | 16 (range, 4–40) | 23 (range, 5–40) | 8 (range, 4–25) | 0.09 |